跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
EVOTAZ - Health Canada Drug Approval Details
Approvals
/
Health Canada
/
EVOTAZ
Authorized
STANDARD
EVOTAZ
bristol-myers squibb canada
🇨🇦 Health Canada
Approval Date
Jul 4, 2025
Approval ID
d059fac88eb89532
Company
bristol-myers squibb canada
Type
Standard
Approval Details
Approval Id
d059fac88eb89532
Drug Approval Canada Name
EVOTAZ
Product Name
EVOTAZ
Status
Cancelled Post Market
Status Date
2017-09-22
Original Market Date
2016-02-11
Din
02446731
Drug Class
Human
Dosage Form
Tablet
Route Of Administration
Oral
Schedule
Prescription
Ahfs
92:92.00
Atc Original
J05AR15 ATANAZAVIR AND COBICISTAT
Atc Name
j 05 ar 15
Aig Number
0257430001
Company Name
bristol-myers squibb canada
Company Address
2344 Boul. Alfred-Nobel, Suite 300, St-Laurent, Quebec, Canada, H4S 0A4
Active Ingredients
COBICISTAT
150 MG
ATAZANAVIR (ATAZANAVIR SULFATE)
300 MG
Authorized
Quick Info
Agency
Health Canada
Country
🇨🇦
Approval Date
Jul 4, 2025
Approval ID
d059fac88eb89532
Type
Standard
Back to Health Canada Approvals